Merck warns doctors to stop prescribing Tredaptive

January 11, 2013 by The Associated Press

Drugmaker Merck says it is suspending its sale of the cholesterol drug Tredaptive and is telling doctors to quit prescribing the medicine.

Tredaptive is available in about 70 countries, including Europe. The drug is not approved in the United States.

Merck last month said initial results from a late-stage study showed that adding Tredaptive to traditional did not lower the risk of heart attack, stroke and related problems.

Results also showed that patients taking the cholesterol were more likely to suffer some serious, non-fatal adverse events.

Merck says it made its decision based in part on a European Medicine Agency committee recommendation.

Merck has advised patients to quit taking the drug only after talking to a physician.

Explore further: Merck says cholesterol drug failed to show benefit

shares

Related Stories

Merck says cholesterol drug failed to show benefit

December 20, 2012

Drugmaker Merck & Co. said it will not seek U.S. approval for its cholesterol drug Tredaptive and is recommending doctors abroad stop prescribing it to new patients, based on failed study results.

FDA backs Vytorin for kidney disease patients

October 31, 2011

(AP) -- The Food and Drug Administration says Merck's cholesterol drug Vytorin helps reduce heart attack, stroke and related problems in patients with kidney disease, a potential new use for the blockbuster drug.

FDA approves first diabetes-cholesterol combo pill

October 7, 2011

(AP) -- The first combination pill for the millions of people with the dangerous combination of diabetes and high cholesterol won U.S. approval Friday, offering convenience - and savings - to patients taking multiple pills.

Recommended for you

Researchers identify source of opioids' side effects

January 17, 2017

A commercially available drug may help drastically reduce two side effects of opioid painkillers—a growing tolerance and a paradoxical increased sensitivity to pain—without affecting the drugs' ability to reduce pain, ...

CVS generic competitor to EpiPen, sold at a 6th the price

January 12, 2017

CVS is now selling a rival, generic version of Mylan's EpiPen at about a sixth of its price, just months after the maker of the life-saving allergy treatment was eviscerated before Congress because of its soaring cost to ...

Many misuse OTC sleep aids: survey

December 29, 2016

(HealthDay)—People struggling with insomnia often turn to non-prescription sleep remedies that may be habit-forming and are only intended for short-term use, according to a new Consumer Reports survey.

The pill won't kill your sexual desire, researchers say

December 15, 2016

Taking the pill doesn't lower your sexual desire, contrary to popular belief, according to research published in the Journal of Sexual Medicine. The authors of the research, from the University of Kentucky and Indiana University ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.